Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic
drugs that improve glycemic control and many other atherosclerosis-related parameters in …

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that govern the
expression of genes responsible for energy metabolism, cellular development, and …

Orlistat, an anti-obesity drug, is a potent and specific inhibitor of intestinal lipases. In light of
the recent US FDA approval of the over-the-counter sale of orlistat (60 mg three times daily) …

Semaglutide is a glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) with a long
elimination half‐life, allowing subcutaneous (sc) administration once per week. Both the …

Elevated serum uric acid (SUA) levels are commonly seen in patients with the metabolic
syndrome (MetS). Several mechanisms, both direct and indirect, connect the increased SUA …

The metabolic syndrome (MetS) is characterized by the presence of central obesity,
impaired glucose metabolism, dyslipidemia and hypertension. Several studies showed that …

Fenofibrate is a fibric acid derivative indicated for use in the treatment of primary
hypercholesterolaemia, mixed dyslipidaemia and hypertriglyceridaemia in adults who have …

Fenofibrate is a fibric acid derivative indicated for the treatment of severe
hypertriglyceridaemia and mixed dyslipidaemia in patients who have not responded to …

The focus of this review is on the role of apolipoprotein C-II (apoC-II) in lipoprotein
metabolism and the potential effects on the risk of cardiovascular disease (CVD). We …

Fat accumulation in the pancreas associated with obesity and the metabolic syndrome
(MetS) has been defined as “non-alcoholic fatty pancreas disease”(NAFPD). The aim of this …